Astral Poly Technik

Accumulate

Annual Report FY20- Survival of Fittest

Over the years, Astral Group has evolved into a robust and resilient organisation. They have been consistently surging ahead on the back of its strong foundation, differentiated strategies, quality offerings and an experienced leadership. With robust capacities, they have marketed its presence across multiple locations to fulfil demand across the country. Prudent financials with low leveraging further aid them in remaining sturdy amidst the challenges in the operating environment. Astral is strongly positioned in organised space and ready to capitalise on the underlying opportunities. With sharp focus on serving the customers through innovative products in the piping and adhesive segments, they remain committed to create enduring value for its stakeholders.

DART View

ASTRA maintained its leadership in the CPVC segment. It had developed a large PVC portfolio in the past decade. With a logical expansion in the adhesive segment, APTL expanded its building materials portfolio. The diversified product portfolio in both piping and adhesive enabled it to play the building material opportunity.

We believe that ASTRA is in the investment phase and will reap long-term benefits of this strategy in the next five years. With new product addition in the Adhesive as well as pipe segment, we feel that revenue growth along with margin profile should get better once economy is on recovery track. The company's growth trajectory remains high and return ratios are also expanding, therefore valuation should remain expensive.

Industry Overview

Over the past five years, domestic plastic pipe industry has clocked a 10% CAGR, Wherein, 60-65% market share accounts to organised players and remaining to unorganised. The major driver behind the growth is Government infrastructural spending, increasing constructions, industrial production, irrigation sector, replacement of aging pipelines, among others. Amongst all plastic pipes, 65% of the industry demand is for UPVC, 15% for CPVC and remaining constitute to others. Along with this, increased focused by the Government in the end user application will be the major contributor in the growth.

MD&A Overview

By adopting innovative technologies and extensive R&D, it continues to set trends with the introduction of new products line. While it has continuously expanded boundaries by setting up plants across India to meet requirement of customers from different locations. During the year, Astral continuously invested in expanding capacities at various plants. With strong focus on promotion, they continuously increase their brand visibility and customer penetration across the country. With strong brand equity, healthy balance sheet and multi-location presence, Astral expects to gain significant market share from unorganised and organised players in the near future. They have continuously invested into product innovation and capacity expansion to improve efficiency, cost effectiveness and deliver reliable solutions to the customers.


Financial Snapshot

Revenues on a consolidated basis was flat at Rs. 25,779 mn. Despite the challenging external environment, it delivered strong gross margins of 38.1% YoY, which was a growth of 382 bps. Operating Cash flow for FY20 was Rs. 4,054 mn as compared to Rs. 3,441 mn in FY19. Free cash flow for the firm on a consolidated level was Rs. 1,921 mn in FY20. Pipe segment volume growth was 7.5% YoY.



СМР	Rs 942
Target / Upside	Rs 1,074 / 14%
BSE Sensex	37,719
NSE Nifty	11,102
Scrip Details	
Equity / FV	Rs 151mn / Rs 1
Market Cap	Rs 142bn
	US\$ 2bn
52-week High/Low	Rs 1,369/Rs 746
Avg. Volume (no)	1,61,118
NSE Symbol	ASTRAL
Bloomberg Code	ASTRA IN
Shareholding Patte	ern Jun'20(%)
Promoters	55.7
MF/Banks/Fls	7.6
FIIs	23.2
Public / Others	13.5

Astral Poly Relative to Sensex



AVP Research: Nidhi Doshi Tel: +91 22 40969795 E-mail: nidhid@dolatcapital.com





Annual Report Macro View

Key Management	No change.				
Board of Directors	Mr. K R Shenoy, Chairman (Independent Director) Mr. Sandeep Engineer (Managing Director) Mrs. Jagruti Engineer (Whole Time Director) Mr. Anil Kumar Jani (Non- Executive Director)				
Auditors	No change. M/s. S R B C & Co. LLP, Cha company.	artered Accountants continu	e to be the audit	ors of the	
Insider Holdings	No Inside Holdings				
	Crisil Rating	FY2020	FY2019		
Credit Ratings	Long Term Bank Facilities	CRISIL AA-/ Stable	CRISIL AA-/ S	table	
	Short Term Bank Facilities	CRISIL A1+	CRISIL A1	+	
Pledged Shares	No pledged shares were held o	during the year.			
Macro-economic factors	various government initiatives unexpected Covid 19 outbrea	-	•	•	
	functioned smoothly despite f	the health crisis, displaying a	a growth rate of 3.	7% during	
		the health crisis, displaying a	a growth rate of 3. FY2020	7% during FY2019	
	FY20.	the health crisis, displaying a	-	-	
	FY20. Shareholding Pattern	the health crisis, displaying a	FY2020	FY2019	
	FY20. Shareholding Pattern A. Promoters	the health crisis, displaying a	FY2020	FY2019	
	FY20. Shareholding Pattern A. Promoters B. Public Shareholding	the health crisis, displaying a	FY2020	FY2019	
	FY20. Shareholding Pattern A. Promoters B. Public Shareholding 1. Institutions:	the health crisis, displaying a	FY2020 55.74	FY2019 53.51	
	FY20. Shareholding Pattern A. Promoters B. Public Shareholding 1. Institutions: a. Mutual Funds	the health crisis, displaying a	FY2020 55.74 8.34	FY2019 53.51 5.73	
	FY20.Shareholding PatternA. PromotersB. Public Shareholding1. Institutions:a. Mutual Fundsb. Banks/Fl	the health crisis, displaying a	FY2020 55.74 8.34 0.53	FY2019 53.51 5.73 0.01	
	FY20. Shareholding Pattern A. Promoters B. Public Shareholding 1. Institutions: a. Mutual Funds b. Banks/FI c. Bodies corp.	the health crisis, displaying a	FY2020 55.74 8.34 0.53 0.15	FY2019 53.51 5.73 0.01	
	FY20.Shareholding PatternA. PromotersB. Public Shareholding1. Institutions:a. Mutual Fundsb. Banks/Flc. Bodies corp.d. Insurance Companies	the health crisis, displaying a	FY2020 55.74 8.34 0.53 0.15 0.02	FY2019 53.51 5.73 0.01 4.97	
	FY20.Shareholding PatternA. PromotersB. Public Shareholding1. Institutions:a. Mutual Fundsb. Banks/FIc. Bodies corp.d. Insurance Companiese. FIIs	the health crisis, displaying a	FY2020 55.74 8.34 0.53 0.15 0.02 2.66	FY2019 53.51 5.73 0.01 4.97 2.54	
	FY20. Shareholding Pattern A. Promoters B. Public Shareholding 1. Institutions: a. Mutual Funds b. Banks/FI c. Bodies corp. d. Insurance Companies e. FIIs f. Foreign portfolio investor	the health crisis, displaying a	FY2020 55.74 8.34 0.53 0.15 0.02 2.66	FY2019 53.51 5.73 0.01 4.97 2.54	
	 FY20. Shareholding Pattern A. Promoters B. Public Shareholding 1. Institutions: a. Mutual Funds b. Banks/FI c. Bodies corp. d. Insurance Companies e. FIIs f. Foreign portfolio investor 2. Non-Institutions: 	the health crisis, displaying a	FY2020 55.74 8.34 0.53 0.15 0.02 2.66 16.76	FY2019 53.51 5.73 0.01 4.97 2.54 19.39	
	 FY20. Shareholding Pattern A. Promoters B. Public Shareholding 1. Institutions: a. Mutual Funds b. Banks/FI c. Bodies corp. d. Insurance Companies e. FIIs f. Foreign portfolio investor 2. Non-Institutions: a. Bodies Corp. 	the health crisis, displaying a	FY2020 55.74 8.34 0.53 0.15 0.02 2.66 16.76 2.67	FY2019 53.51 5.73 0.01 4.97 2.54 19.39 2.39	
	FY20.Shareholding PatternA. PromotersB. Public Shareholding1. Institutions:a. Mutual Fundsb. Banks/FIc. Bodies corp.d. Insurance Companiese. FIIsf. Foreign portfolio investor2. Non-Institutions:a. Bodies Corp.b. Individuals		FY2020 55.74 8.34 0.53 0.15 0.02 2.66 16.76 2.67 8.38	FY2019 53.51 5.73 0.01 4.97 2.54 19.39 2.39 10.82	

Source: Company, DART





What's New

For every challenge encountered, there is an opportunity for growth. One who is stronger and persistent, consistently reaches new heights by proactively calibrating its strategies and strengthening preparedness to face the uncertainties.

- Astral has extended its product basket by supplying double wall corrugated piping solutions in the infrastructure segment through Rex Polyextrusion Private Limited.
- Astral has stepped up by supplying double wall corrugated piping solutions for Sewerage and Stormwater.
- Astral's tailor-made product, Hauraton, is a reliable name in the surface drainage solutions. While their Wire Guard, TeleRex are designed to fulfil the needs of Cable Protection segment.
- New piping plant in Odisha will be ready by FY 21, which will help them expand in the North-East markets.
- ASTRA also acquired additional land measuring 157,648 sq. meter, adjacent to their plants located at Sangli, Hosur, Santej and Odisha.
- PEX-A-PRO has been growing consistently with great response from the customers. They further plan to manufacture the high quality PEX product in-house by sourcing the best technology and machinery from the global experts.
- Brought famous Bollywood celebrity, Ranveer Singh, as the new brand ambassador which will further add to the brand's visibility.
- Launched a unique loyalty program for plumbers across the country and a dealer attachment program to strengthen the distributor connect.
- Initiated structural changes in Resinova to strengthen distribution system. Post the structural corrections, they are positive that the adhesive segment will deliver healthy growth in the coming years.

Capacity Expansions

- During FY20, Astral increased its installed capacity by 16% from 205,290 M.T. to 238,730 M.T.
- They utilised its capacity to the tune of 135,636 M.T. as against 120,821 M.T. YoY. which shows a utilisation growth of 12%.
- During FY20, have incurred capital expenditure to the tune of Rs. 2,063 Mn towards plant & machineries, factory building and other capital expenditure.
- Enhanced manufacturing strength by adding capacities for various product lines in plants at Ghiloth, Hosur, Sangli, Dholka, Santej and Sitarganj.
- New piping manufacturing plant coming up at Bhubaneswar, Odisha, will allow them to address the demand in the North-East region.
- Piping Production Capacity: 2,46,765 MMTPA
- Adhesive Production Capacity: 86,817 MMTPA





With steady performance during the year, we stand confident even in turbulent times. **Diversified product** range, extensive distribution network, and cutting-edge technologies, are the cornerstone of our business strategy. More *importantly, robust* balance sheet quality and manufacturing efficiencies remain the distinctive characteristics of our operations.

Our solid foundation, consistent focus on bringing innovative products and robust financial strength yielded desired value for all.

From MD's Desk

- Though Astral faced temporary disruption due to Covid 19 in their manufacturing operations, robust IT infrastructure ensured uninterrupted services for customers by enabling seamless 'work from home' facility.
- Anti-dumping duty imposed on CPVC resin proved to be an opportunity for Astral to gain market share, as one of the leading organised industry players.
- State-of-the art manufacturing units and distribution channels across the country enabled to timely deliver products to customers despite the nationwide lockdown.
- With right expansion strategies, they are well-poised to cater a larger customer base, optimise logistic cost and explore potential opportunities in the country.
- They are well positioned to surge ahead with sturdy financials, geographical presence and industry reputation.

From CFO's Desk

- At Astral, key strategic objective continues to revolve around maintaining strong balance sheet quality and working capital cycle along with adequate cash flows generation.
- In the coming year, focus will be on these parameters and improvement of ROC and free cash flow by reducing incremental Capex and increasing capacity utilisation of plants.
- They are optimistic that the adhesive division will deliver better performance in the long-run, backed by refined structure, innovative offerings and skilled workforce.
- ASTRA aims to be debt-free by the end of the year 2021.





Key Takeaways from the MD&A

To be a truly global, highperforming organisation delivering quality products and services to its customers and attain leadership position in the industries we operate in.

- Indian plastic pipe industry is estimated to register a 10% CAGR by 2024-25 to reach Rs. 500 bn.
- In Q1FY21, earnings of pipe manufacturers will be impacted to some extent owing to slowdown caused by the COVID-19.
- Relative to other sectors, it is still resilient as the Government gave boost to agriculture and housing sector through handsome stimulus package.
- Amid economic slowdown, several unorganised and organised players might face trouble owing to liquidity issues and weak balance sheet. As a result, organised players with robust financials are likely to gain sizeable market share.

Indian Adhesive Industry

Indian Piping Industry

- The major demand for adhesive comes from the packaging and automotive industry in the country. Increase in disposable income levels and booming retail markets are propelling growth in packaging industry which is conducive for driving demand for adhesives.
- Rapid urbanisation coupled with growing infrastructure and real estate construction projects is further projected to fuel the demand.
- The India Adhesives & Sealants market is expected to record a CAGR of 11.17% during the forecast period of 2019–2024.

Astral's Piping Segment

- Astral's piping business has consistently outperformed the industry growth.
- The spectacular growth momentum is led by capacity expansion, spurring volume growth, reputed brand name and large distribution network.
- The recently introduced product PEX-A-PRO has seen positive response from the market, with consistent business.
- Added infrastructure products in piping portfolio through Rex Polyextrusion.
- The piping segment's revenues in FY20 stood at Rs 20,428 mn. EBIDTA improved by 20.7% to Rs 3,806 mn in FY20 from Rs 3,154 mn in FY19. Net Profit stood at Rs 2,008 mn in FY20 as against Rs 1,414 mn in FY19, showing an increase of 42.0%.


Astral's Adhesive Segment

- Astral has leveraged its geographical strength and existing distribution network along with its own cross-selling opportunities to grow in the adhesive segment.
- With right structural changes and strategies, Resinova is expected to capture higher market share in the adhesive and sealant segment.
- They recently launched an instant hand sanitizer 'Resi Shield' to help curb the COVID-19 pandemic.
- Combined Revenue of Resinova and Seal IT stood at Rs 5,830 million, while EBIDTA was recorded at Rs 765 million in the FY20






Exhibit 1: Piping Capacity vs Utilisation




Source: Company, DART

Exhibit 2: Piping Segment Gross Margin (%)




Source: Company, DART

Exhibit 4: Adhesive Segment Gross Margin (%)



Source: Company, DART

Exhibit 3: Piping Segment Sales Volume ('000 MT)



Source: Company, DART

36 34.3 33.3 34 32 31.2 30 28.4 28.1 28 26 FY16 FY17 FY18 FY19 FY 20

Exhibit 5: Combined Gross Margin (%)



Source: Company, DART



Exhibit 6: Business Segment Performance (%)

Business	FY 20	FY 19
Piping	77	74
Adhesives	23	26

Source: Company, DART

Reduction in Adhesives was mainly because company was doing structured corrections from Tier 3 sales structure to Tier 2 sales structure.

Distribution & Branding

- Astral has a large distribution network across India with strong reach in West and South India.
- They are planning to increase its reach in the North-East as well by setting a manufacturing plant in Bhubaneswar, Odisha.
- In the piping segment they have 800+ distributors and dealers. In the adhesive segment they have 1,300+ distributors and 1,30,000+ dealers.
- Astral has continuously invested in brand & promotional activities through Bollywood movies, associate sponsor of Indian Premier League teams among others which has helped the Company gain exceptional visibility and market share.
- Astral has its new brand ambassador Ranveer Singh on board for next three years from now.

Opportunities and Growth Drivers

- Consolidation in industry: Post GST, unorganized players were finding it difficult to survive, now with Covid 19, companies with high debt and weak cash flow are bound to head towards consolidation, which will allow opportunities for organized players to acquire local players at lower valuations.
- Government initiatives: The Government schemes such as Housing for All" by 2022, "Nal se Jal" by 2024, project AMRUT & Swachh Bharat Mission, National Rural Drinking Water Programme, among others augurs well for the plastic pipe industry.
- Replacement of aging pipes: Traditional pipe material like iron, steel and concrete used in the cities and buildings are getting older and corroded, reducing its stability. PVC/CPVC pipes are highly recommended as replacement by the plumbers owing to its lower cost and ease of installations.

Challenges

- Cost of raw material: The higher raw material prices can increase the production cost of the players operating in the industry. However, the increase in raw material prices does not impact pipe manufacturing players as the higher cost is passed down to the downstream industry users.
- Stagnation in the construction industry: Slow pace of construction activities can hamper the margins of the pipe industry players. However, the industry is less likely to be impacted owing to sustained demand for replacement of traditional pipes and shift from unorganised to organised players.
- Slowdown in the capex of the downstream industry: The downstream industry's cautious approach towards capital expenditure in the projects can affect the order books of the plastic pipe players.





Profit & Loss Analysis

- Net sales witnessed growth of 2.8% YoY. The sales and volumes were impacted due to lockdown in last 10 days of March'20, due to natiowide lockdown.
- EBITDA margin increased from 15.4% in FY19 to 17.2% in FY20 while the gross margin rose from 34.3% to 38.1% during the same period. Also, the PAT margin rose from 8% in FY19 to 9.7% in FY20. In the piping segment margins grew due to inventory gain and increase in share of value added products.
- Costs of materials de-grew by about 3.2% over the previous year at Rs 16 million mainly due to volatile crude prices.
- Profit before Tax increased by 7% over previous year to Rs 3 billion. Tax rate (consolidated basis) for the current year was 18.4% compared to 30% in the previous year.
- Profit after Tax increased by 26.5% over the previous year to Rs 2.5 billion.
- Other expenses increased by 8.5% Rs3.6 billion. Employee expenses increased by 25.9% YoY to Rs 1.8 billion
- The directors recommended two interim dividends of Rs 0.4 per share and Rs 0.6 per share.
- Interest cost increased by 23.3% to Rs394 million from Rs 320 million. Return on Net Worth increased from 17.2% to 18% in FY20.

Balance Sheet Analysis

- Net worth has increased by 18% on account of increase in tangible assets as the company has constructed a building in Ahmedabad for its CSR activities and various investments in Plants and Equipment's.
- Loan funds have decreased to the tune of 54%. They plan to become debt free by year 2021.
- Cash and bank balances have increased by 33% as balances with banks in current accounts and deposit accounts have increased.
- Inventories have increased by 37% on account of pile up due to lockdown in last 10 days of March'20.
- Gross block of fixed assets increased by 24% but net block increased by 18%. There was 47% rise in accumulated depreciation.
- In Q4FY20, the closing inventory level increased with reduced receivables.

Cash Flow Analysis

- Operating Cash flow increased 18% YoY.
- Free cash flow has increased by 54% as depreciation and write-offs have gone up accompanied by a rise in net interest expenses.

With a robust business model, wide gamut of value-added products and strong brand visibility across length and breadth of the country, we are well placed to serve our customers even in the turbulent times.





Key Financial Ratios

Exhibit 7: Standalone

Ratios	FY20	FY19	% chg
Debtor turnover (Days)	25 days	43 days	(42.00)
Inventory turnover (days)	75 days	57 days	32.00
Interest coverage ratio	15.97	10.96	45.71
Current Ratio	1.42	1.34	5.97
Long term debt equity Ratio	0.09	0.15	(40.00)
EBITDA Margin	18.63	16.46	13.16
PAT Margin	9.83	7.38	33.17
Return on Net Worth	16.17	13.46	20.11

Source: Company, DART

Exhibit 8: Consolidated

Ratios	FY20	FY19	% chg
Debtor turnover (Days)	32 days	50 days	(38.00)
Inventory turnover (days)	77 days	58 days	32.76
Interest coverage ratio	15.51	12.03	28.93
Current Ratio	1.57	1.48	5.55
Long term debt equity Ratio	0.11	0.19	(41.79)
EBITDA Margin	17.59	15.82	11.13
PAT Margin	9.68	7.87	23.04
Return on Net Worth	17.77	17.00	4.52

Source: Company, DART











Exhibit 10: Return on Net Worth




Source: Company, DART





Source: Company, DART






Source: Company, DART




Exhibit 12: Profit and Effective Tax Rate



Source: Company, DART

Exhibit 14: Dividend Payout (%)



Source: Company, DART





Profit a	and Loss	Account
----------	----------	---------

(Rs Mn)	FY19A	FY20A	FY21E	FY22E
Revenue	25,073	25,779	23,803	26,102
Total Expense	21,224	21,350	19,942	21,028
COGS	16,477	15,957	15,795	16,927
Employees Cost	1,391	1,752	911	1,054
Other expenses	3,355	3,641	3,237	3,046
EBIDTA	3,849	4,429	3,860	5,074
Depreciation	814	1,079	988	1,268
EBIT	3,035	3,350	2,873	3,807
Interest	320	394	326	401
Other Income	154	121	150	300
Exc. / E.O. items	0	0	0	0
EBT	2,870	3,077	2,697	3,705
Tax	861	565	618	889
RPAT	1,973	2,496	2,059	2,796
Minority Interest	0	0	0	0
Profit/Loss share of associates	(36)	(16)	(20)	(20)
АРАТ	1,973	2,496	2,059	2,796

Bal	lance	Sheet

(Rs Mn)	FY19A	FY20A	FY21E	FY22E
Sources of Funds				
Equity Capital	120	151	151	151
Minority Interest	150	168	180	200
Reserves & Surplus	12,657	14,878	17,054	19,413
Net Worth	12,777	15,029	17,205	19,564
Total Debt	2,753	1,270	1,300	1,300
Net Deferred Tax Liability	533	429	500	550
Total Capital Employed	16,212	16,896	19,185	21,614

Net Block	8,517	9,996	10,109	11,001
CWIP	3,346	2,997	3,267	3,527
Investments	2	2	2	2
Current Assets, Loans & Advances	9,130	9,898	9,401	11,239
Inventories	3,958	5,404	4,107	5,091
Receivables	3,391	2,278	1,631	1,958
Cash and Bank Balances	981	1,301	2,088	2,709
Loans and Advances	515	465	1,252	1,159
Other Current Assets	283	448	320	321
Less: Current Liabilities & Provisions	4,780	5,995	3,592	4,153
Payables	3,897	4,754	3,660	3,660
Other Current Liabilities	882	1,241	(68)	493
sub total				
Net Current Assets	4,350	3,903	5,809	7,086
Total Assets	16,212	16,896	19,185	21,614







Particulars	FY19A	FY20A	FY21E	FY22E
(A) Margins (%)				
Gross Profit Margin	34.3	38.1	33.6	35.2
EBIDTA Margin	15.4	17.2	16.2	19.4
EBIT Margin	12.1	13.0	12.1	14.6
Tax rate	30.0	18.4	22.9	24.0
Net Profit Margin	7.9	9.7	8.7	10.7
(B) As Percentage of Net Sales (%)				
COGS	65.7	61.9	66.4	64.8
Employee	5.5	6.8	3.8	4.0
Other	13.4	14.1	13.6	11.7
(C) Measure of Financial Status				
Gross Debt / Equity	0.2	0.1	0.1	0.1
Interest Coverage	9.5	8.5	8.8	9.5
Inventory days	58	77	63	71
Debtors days	49	32	25	27
Average Cost of Debt	13.8	19.6	25.4	30.9
Payable days	57	67	56	51
Working Capital days	63	55	89	99
FA T/O	2.9	2.6	2.4	2.4
(D) Measures of Investment				
AEPS (Rs)	13.1	16.5	13.6	18.5
CEPS (Rs)	18.5	23.7	20.2	26.9
DPS (Rs)	0.6	1.0	3.5	4.5
Dividend Payout (%)	4.2	6.0	25.7	24.3
BVPS (Rs)	84.6	99.5	113.9	129.6
RoANW (%)	17.2	18.0	12.8	15.2
RoACE (%)	16.2	17.6	13.3	15.8
RoAIC (%)	22.3	21.7	17.6	21.1
(E) Valuation Ratios				
CMP (Rs)	942	942	942	942
P/E	72.0	57.0	69.1	50.8
Mcap (Rs Mn)	1,42,182	1,42,182	1,42,182	1,42,182
MCap/ Sales	5.7	5.5	6.0	5.4
EV	1,43,951	1,42,149	1,41,391	1,40,771
EV/Sales	5.7	5.5	5.9	5.4
ev/ebitda	37.4	32.1	36.6	27.7
P/BV	11.1	9.5	8.3	7.3
Dividend Yield (%)	0.1	0.1	0.4	0.5
(F) Growth Rate (%)				
Revenue	19.1	2.8	(7.7)	9.7
EBITDA	21.5	15.1	(12.8)	31.4
EBIT	16.9	10.4	(14.2)	32.5
PBT	14.4	7.2	(12.4)	37.4
APAT	12.3	26.5	(17.5)	35.8
EPS	12.3	26.5	(17.5)	35.8

(Rs Mn)	FY19A	FY20A	FY21E	FY22E
CFO	3,441	4,054	4,253	3,245
CFI	(2,934)	(3,177)	(1,806)	(2,008)
CFF	(49)	(1,630)	(1,659)	(616)
FCFF	1,245	1,921	3,002	826
Opening Cash	435	892	1,301	2,088
Closing Cash	892	139	2,088	2,709
E – Estimates				





DART RATING MATRIX

Total Return Expectation (12 Months	Total Return	Expectation	(12 Months
-------------------------------------	---------------------	-------------	------------

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

Rating and Target Price History



Rating	TP (Rs.)	Price (Rs.)
Accumulate	1,487	1,219
BUY	1,388	1,123
BUY	1,340	1,198
Buy	1,126	879
Accumulate	907	812
	Accumulate BUY BUY Buy Accumulate	Accumulate 1,487 BUY 1,388 BUY 1,340 Buy 1,126

*Price as on recommendation date

DART Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747				
Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745				
CONTACT DETAILS							
Equity Sales	Designation	E-mail	Direct Lines				
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709				
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735				
Yomika Agarwal	VP - Equity Sales	yomika@dolatcapital.com	+9122 4096 9772				
Jubbin Shah	VP - Derivatives Sales	jubbins@dolatcapital.com	+9122 4096 9779				
Ashwani Kandoi	AVP - Equity Sales	ashwanik@dolatcapital.com	+9122 4096 9725				
Lekha Nahar	AVP - Equity Sales	lekhan@dolatcapital.com	+9122 4096 9740				
Equity Trading	Designation	E-mail	-				
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728				
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707				
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702				
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715				
Dinesh Mehta	Co- Head Asia Derivatives	dinesh.mehta@dolatcapital.com	+9122 4096 9765				
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705				

Dolat Capital Market Private Limited. Sunshine Tower, 28th Floor, Senapati Bapat Marg, Dadar (West), Mumbai 400013



Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. Entity/ persons only: This research report is a product of Dolat Capital Market Private Limited., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Dolat Capital Market Private Limited. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person or entity.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Dolat Capital Market Private Limited. has entered into an agreement with a U.S. registered broker-dealer Ltd Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer/Entity as informed by Dolat Capital Market Private Limited. from time to time.

Dolat Capital Market Private Limited.

Corporate Identity Number: U65990DD1993PTC009797 Member: BSE Limited and National Stock Exchange of India Limited. SEBI Registration No: BSE - INB010710052 & INF010710052, NSE - INB230710031& INF230710031, Research: INH000000685 Registered office: Office No. 141, Centre Point, Somnath, Daman – 396 210, Daman & Diu Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com